Phase 2 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with early Alzheimer's disease, with memory test scores that suggest mild memory problems (your doctor can confirm this based on specific test results).
• You are between 60 and 85 years old.
• You are generally in good health, with no conditions likely to affect how the study is run.
• You have been on the same medications for at least 8 weeks before the study, and this is expected to stay the same throughout the study.
• You are not pregnant, breastfeeding, or able to become pregnant (women must be at least 2 years past menopause or have had a surgical procedure to prevent pregnancy); if you could become pregnant, your partner must use barrier contraception throughout the study.
• A special brain scan (called an amyloid PET scan) shows a build-up of a protein called amyloid in your brain — or you have previous test results showing this (confirm with trial site).
• You are able to understand the study and agree to take part by signing a consent form.
• You have someone in your life (such as a family member or close friend) who knows you well and has regular contact with you, and who can participate as a study partner.

Who may not be able to join:

• You have another significant brain or nervous system condition, such as Parkinson's disease, a history of stroke, a brain tumour, epilepsy, multiple sclerosis, or certain other neurological disorders.
• You have serious or poorly controlled health conditions, such as uncontrolled high blood pressure, uncontrolled diabetes, or significant heart, lung, kidney, liver, or hormone-related problems.
• You have a history of an autoimmune disease (a condition where the immune system attacks the body).
• You have used medications that affect the immune system, or steroid treatments (including nasal sprays), in the past month.
• You have had a major depressive episode in the past year, or have a history of bipolar disorder or schizophrenia.
• You have had problems with alcohol or drug misuse or dependence in the past two years.
• You have had cancer in the past 3 years.
• Your routine blood or urine tests at screening show significant abnormalities (confirm with trial site).
• You are currently taking part in, or have taken part in, another clinical drug trial in the past 30 days.
• A genetic test shows a specific variation in a gene called TSPO that would affect how a particular scan works in this study (confirm with trial site).
• You have a known sensitivity or allergy to a substance called florbetapir F18, which is used in one of the brain scans.
• You currently have an active COVID-19 infection.
• Your amyloid PET scan does not show a build-up of amyloid protein in the brain.
• You have received a COVID-19 vaccine in the past 10 days, or any other vaccine in the past 7 days, at the time of your first dose in the study.

Important: Always verify eligibility with the trial site directly before applying.